X4 Pharmaceuticals Inc (XFOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.60 Million) by net assets ($168.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XFOR defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
X4 Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how X4 Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
X4 Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Richtech Robotics Inc. Class B Common Stock
NASDAQ:RR
|
-0.005x |
|
Lifeway Foods Inc
NASDAQ:LWAY
|
0.003x |
|
Cognor S.A.
WAR:COG
|
-0.068x |
|
Youngtek Electronics
TWO:6261
|
0.043x |
|
Nanjing TDH Technology Co. Ltd. A
SHE:301378
|
N/A |
|
Silvaco Group, Inc. Common Stock
NASDAQ:SVCO
|
-0.144x |
|
Guangshen Railway Company Limited
F:GRCH
|
0.026x |
|
Firan Technology Group Corporation
TO:FTG
|
0.073x |
Annual Cash Flow Conversion Efficiency for X4 Pharmaceuticals Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of X4 Pharmaceuticals Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see XFOR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $186.29 Million | $-85.62 Million | -0.460x | +92.22% |
| 2024-12-31 | $22.15 Million | $-130.90 Million | -5.910x | -212.91% |
| 2023-12-31 | $51.10 Million | $-96.51 Million | -1.889x | -81.40% |
| 2022-12-31 | $74.05 Million | $-77.10 Million | -1.041x | +5.41% |
| 2021-12-31 | $64.41 Million | $-70.91 Million | -1.101x | -36.25% |
| 2020-12-31 | $72.80 Million | $-58.82 Million | -0.808x | -117.26% |
| 2019-12-31 | $129.22 Million | $-48.05 Million | -0.372x | +68.40% |
| 2018-12-31 | $21.60 Million | $-25.42 Million | -1.177x | -147.89% |
| 2017-12-31 | $58.71 Million | $-27.87 Million | -0.475x | -136.69% |
| 2016-12-31 | $-16.72 Million | $-21.64 Million | 1.294x | -47.68% |
| 2015-12-31 | $-4.37 Million | $-10.82 Million | 2.473x | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more